227 related articles for article (PubMed ID: 32645760)
1. TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder.
Bertz S; Stöhr R; Gaisa NT; Wullich B; Hartmann A; Agaimy A
Histopathology; 2020 Dec; 77(6):949-962. PubMed ID: 32645760
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma.
Montgomery EA; Shuster DD; Burkart AL; Esteban JM; Sgrignoli A; Elwood L; Vaughn DJ; Griffin CA; Epstein JI
Am J Surg Pathol; 2006 Dec; 30(12):1502-12. PubMed ID: 17122505
[TBL] [Abstract][Full Text] [Related]
3. Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder.
Westfall DE; Folpe AL; Paner GP; Oliva E; Goldstein L; Alsabeh R; Gown AM; Amin MB
Am J Surg Pathol; 2009 Jan; 33(1):99-105. PubMed ID: 18941404
[TBL] [Abstract][Full Text] [Related]
4. Pseudosarcomatous myofibroblastic proliferations of the urinary bladder are neoplasms characterized by recurrent FN1-ALK fusions.
Acosta AM; Demicco EG; Dal Cin P; Hirsch MS; Fletcher CDM; Jo VY
Mod Pathol; 2021 Feb; 34(2):469-477. PubMed ID: 32908253
[TBL] [Abstract][Full Text] [Related]
5. Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder.
Sukov WR; Cheville JC; Carlson AW; Shearer BM; Piatigorsky EJ; Grogg KL; Sebo TJ; Sinnwell JP; Ketterling RP
Mod Pathol; 2007 May; 20(5):592-603. PubMed ID: 17396140
[TBL] [Abstract][Full Text] [Related]
6. Sarcomatoid Urothelial Carcinoma of the Bladder: Analysis of 28 Cases With Emphasis on Clinicopathologic Features and Markers of Epithelial-to-Mesenchymal Transition.
Sanfrancesco J; McKenney JK; Leivo MZ; Gupta S; Elson P; Hansel DE
Arch Pathol Lab Med; 2016 Jun; 140(6):543-51. PubMed ID: 27031776
[TBL] [Abstract][Full Text] [Related]
7. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
8. GATA3 expression in sarcomatoid urothelial carcinoma of the bladder.
Fatima N; Osunkoya AO
Hum Pathol; 2014 Aug; 45(8):1625-9. PubMed ID: 24824028
[TBL] [Abstract][Full Text] [Related]
9. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
[TBL] [Abstract][Full Text] [Related]
10. ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder.
Tsuzuki T; Magi-Galluzzi C; Epstein JI
Am J Surg Pathol; 2004 Dec; 28(12):1609-14. PubMed ID: 15577680
[TBL] [Abstract][Full Text] [Related]
11. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence in-situ hybridization for the detection of anaplastic lymphoma kinase alterations.
Choi E; Williamson SR; Montironi R; Zhang S; Wang M; Eble JN; Grignon DJ; Lopez-Beltran A; Idrees MT; Baldridge LA; Scarpelli M; Jones CL; Wang L; MacLennan GT; Osunkoya AO; Cheng L
Histopathology; 2015 Jul; 67(1):20-38. PubMed ID: 25406945
[TBL] [Abstract][Full Text] [Related]
13. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
14. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
Borah S; Xi L; Zaug AJ; Powell NM; Dancik GM; Cohen SB; Costello JC; Theodorescu D; Cech TR
Science; 2015 Feb; 347(6225):1006-10. PubMed ID: 25722414
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory myofibroblastic tumor of the bladder.
Alderman M; Kunju LP
Arch Pathol Lab Med; 2014 Oct; 138(10):1272-7. PubMed ID: 25268188
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.
Wang X; Lopez-Beltran A; Osunkoya AO; Wang M; Zhang S; Davidson DD; Emerson RE; Williamson SR; Tan PH; Kaimakliotis HZ; Baldridge LA; MacLennan GT; Montironi R; Cheng L
Future Oncol; 2017 Apr; 13(8):705-714. PubMed ID: 28052688
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder.
Paner GP; Annaiah C; Gulmann C; Rao P; Ro JY; Hansel DE; Shen SS; Lopez-Beltran A; Aron M; Luthringer DJ; De Peralta-Venturina M; Cho Y; Amin MB
Hum Pathol; 2014 Jul; 45(7):1473-82. PubMed ID: 24780825
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
[TBL] [Abstract][Full Text] [Related]
19. p-120 Catenin is a Useful Diagnostic Biomarker for Distinguishing Plasmacytoid and Sarcomatoid Variants From Conventional Urothelial Carcinoma.
Acosta AM; Barletta J; Sonpavde G; Schnitt S; Hirsch MS
Arch Pathol Lab Med; 2021 Aug; 145(8):1000-1008. PubMed ID: 33237989
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathologic features and immunophenotype of pseudosarcomatous myofibroblastic proliferation of urinary bladder].
Zhang YH; Zhang XR; Yu J; Li HL
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):585-590. PubMed ID: 30107662
[No Abstract] [Full Text] [Related]
[Next] [New Search]
